



# Proteomics International

LABORATORIES LTD

ASX/Media Release

23 October 2018

ASX code: PIQ

## Proteomics Non-Executive Director Dr John Dunlop to retire at 2018 Annual General Meeting

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), announces that its non-executive director Dr John Dunlop will retire at the close of the company's 2018 Annual General Meeting, to be held 22nd November 2018.

Dr Dunlop has been a non-executive director since the company was incorporated in 2014, and prior to that served as Chairman of Proteomics International Pty Ltd from its formation in 2001.

Proteomics International Managing Director Dr Richard Lipscombe said, "John has acted as a wonderful sounding board for the development and expansion of Proteomics International into the world-leading diagnostics and analytical services company we are today. We gratefully acknowledge his service to our company during an expansive career, and wish John the very best for his retirement."

ENDS

**For further information please contact:**

Dr Richard Lipscombe  
Managing Director  
Proteomics International Laboratories Ltd  
T: +61 8 9389 1992  
E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com)

Susan Fitzpatrick-Napier  
[Public Relations & Media Contact]  
Digital Mantra Group  
T: +61 2 8218 2144  
E: [team@dmgpr.com](mailto:team@dmgpr.com)

**About Proteomics International Laboratories (PILL) ([www.proteomicsinternational.com](http://www.proteomicsinternational.com))**

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. It received the world's first ISO 17025 laboratory accreditation for proteomics services, and operates from state-of-the-art facilities located on Perth's QEII Medical Campus.

Proteomics International's business model is centred on the commercialisation of the company's world-leading test for diabetic kidney disease, PromarkerD, whilst using its proprietary Promarker™ technology platform to create a pipeline of novel diagnostic tests, and offset the cash burn from R&D and product development through provision of specialist analytical services.

Proteomics International Laboratories Ltd

ABN 78 169 979 971

Box 3008, Broadway, Nedlands, WA 6009, Australia

T: +61 8 9389 1992 | E: [enquiries@proteomicsinternational.com](mailto:enquiries@proteomicsinternational.com) | W: [www.proteomicsinternational.com](http://www.proteomicsinternational.com)